HHS Peptide Policy 2026: Are Peptides Legal Now?

HHS Peptide Policy 2026: Are Peptides Legal Now?
November 11, 2026
Reading Time: 10 mins
Peptide News Regulation HHS & FDA
News analysis · November 11, 2026

Are peptides legal now? The October 2026 HHS policy lets US compounding pharmacies prepare six peptides on prescription. It does not approve them, and it does not cover research chemicals, blends or most other peptides. The public comment period closes on November 13.

By the Ordinary Peptides Research Team · Updated
Quick answer

Partly. Since October 30, 2026, HHS has said it will not take enforcement action against state-licensed 503A pharmacies and physicians that compound BPC-157, TB-500, KPV, MOTS-c, Epitalon or Semax for a specific patient with a prescription, provided they meet ten conditions. None of these peptides is FDA-approved. The policy is a draft open for comment until November 13, 2026, and it does not cover research-use-only products, dietary supplements, blends or other peptides.

What HHS Announced

On October 28, 2026, the Office of the HHS Secretary released the "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", signed by Secretary Robert F. Kennedy Jr. The Federal Register published the notice on October 30 (FR Doc. 2026-22192, docket HHS-OASH-2026-0496) [1][2].

The policy names six peptides, the same six that the FDA's Pharmacy Compounding Advisory Committee recommended in July 2026 [3]:

"Enforcement discretion" means the government says it will not act against certain conduct that would otherwise break the rules. Normally a 503A pharmacy can compound from a bulk ingredient only if that ingredient is part of an approved drug, has a USP monograph or is on the FDA's 503A bulks list. None of the six meets those criteria [4]. The policy fills that gap until the FDA issues a final rule on each peptide.

The approach is unusual. Compounding policy normally comes from the FDA. In this case the Secretary's office issued it directly, and news reports say most FDA scientific staff opposed it [5].

What the Policy Covers and What It Doesn't

Covered Not covered
State-licensed 503A pharmacies, federal facilities and licensed physicians [4] 503B outsourcing facilities, which compound in bulk without individual prescriptions [4][6]
One of the six listed peptides in the exact form described in Appendix A [6] Any other peptide, for example CJC-1295, ipamorelin, tesamorelin or retatrutide
Products with a single listed peptide as the active ingredient [7] Peptide blends such as BPC-157 + TB-500
Patient-specific prescriptions [4][6] Products sold as research chemicals or dietary supplements [7]
Approved routes for each peptide, for example BPC-157 subcutaneous, intramuscular, oral or topical; Semax intranasal only [6][8] Routes not listed for that peptide

The policy also does not override state law. 503A pharmacies are regulated mainly by state boards of pharmacy, and states can still restrict these peptides on their own [9].

The Conditions Pharmacies Must Meet

Law-firm summaries list ten conditions [4][9]. In plain terms:

  • Supply chain: the bulk peptide must come from an FDA-registered manufacturer that follows current good manufacturing practice. If a distributor is involved, the original manufacturer must still be identified [8].
  • Certificate of analysis: every lot needs a valid COA that names the manufacturing site and covers identity, purity, potency and impurities, tested to the criteria in Appendix B [8].
  • Oral forms: the pharmacy must keep evidence that the specific oral formulation reaches adequate bioavailability in humans [9].
  • Devices: only FDA-cleared syringes may be co-packaged with the product [8].
  • Labeling: the label must say "This is a compounded drug product. Not for resale." and explain how to report problems [8].
  • Reporting: serious adverse events and quality problems go to FDA MedWatch, whether or not they appear drug-related [8].

Many of these requirements, such as traceable manufacturers, lot-level COAs and event reporting, are things the grey market lacks. HHS has said one aim is to discourage the widespread use of research-use-only peptides from foreign manufacturers [8].

The policy makes six peptides available on prescription from US pharmacies. It does not approve them, and it does not legalize research chemicals for human use.
Type of product Status in the US
FDA-approved peptide drugs (insulin, semaglutide, tirzepatide) Legal with a prescription
The six peptides compounded by a 503A pharmacy on prescription Not approved, but covered by HHS enforcement discretion if all conditions are met
Other unapproved peptides sold for human use Unapproved drugs. The FDA sent warning letters to online sellers in March, June and August 2026 [10]
"Research use only" peptides Outside the policy. The FDA has said a research label does not protect a seller whose site suggests human use [10]
Investigational drugs (retatrutide) Not approved. Lilly plans to file with the FDA in Q1 2027 [11]
Any of these in competitive sport BPC-157 is prohibited under WADA S0 and TB-500 under S2 [12]

Outside the US

Other regulators are moving the other way. On October 28, 2026, a Victorian coroner linked the death of Australian actor Richard Norton to the unapproved peptides CJC-1295 and ipamorelin. The coroner recommended that the Therapeutic Goods Administration consider limiting such peptides to clinical trials only [13]. In the Netherlands, customs reported stopping hundreds of peptide shipments by courier through September 2026 [14].

Why the Policy Is Disputed

The case made for it

HHS says the policy gives patients "a more controlled alternative" to the black market by moving supply to licensed US compounders with traceable ingredients, quality testing and safety reporting [5]. Supporters, including peptide-medicine groups and compounding pharmacies, argue that demand already exists and that regulated supply is safer than unregulated imports [3].

The case against it

FDA briefing documents recommended against listing all seven peptides reviewed in July, citing thin human data and unresolved questions about impurities and immunogenicity [3]. Critics point out that several committee members had ties to the peptide industry. The Partnership for Safe Medicines has petitioned the FDA, and CSPI argues the process did not follow the FDA's listing criteria [15][16]. A JAAOS review published online on October 27 concluded that routine clinical use of BPC-157 and TB-500 cannot currently be recommended [17].

The November 13 Deadline and What Comes Next

The policy was published as a draft with a short comment window. Anyone can comment on Regulations.gov under docket HHS-OASH-2026-0496 until November 13, 2026 [2]. HHS says it may revise the policy after reading the comments, or if safety signals or product-quality problems appear [2].

  • Telehealth is getting ready. Hims & Hers has a "Peptides+" waitlist page that lists BPC-157 and TB-500 as coming soon, alongside sermorelin, NAD+ and glutathione. The company had said it would wait for final FDA rules before selling the six peptides under review [18][19].
  • FDA rulemaking. Formal listing on the 503A bulks list requires notice-and-comment rulemaking, which usually takes 12–24 months [3].
  • More peptides. A second advisory committee meeting on five more peptides is expected by February 2027 [3].

We track each step on our peptide news page.

Frequently Asked Questions

Are peptides legal in the US now?

It depends on the peptide and how it is supplied. FDA-approved peptide drugs are legal with a prescription. Under the October 2026 HHS policy, six unapproved peptides may be compounded by licensed 503A pharmacies on a patient-specific prescription. Other unapproved peptides sold for human use remain unapproved drugs.

Is BPC-157 still banned?

BPC-157 is not FDA-approved. It left the FDA's Category 2 list in April 2026, and since October 2026 licensed pharmacies may compound it on prescription under HHS enforcement discretion. It remains prohibited in sport under WADA's S0 category.

Do you need a prescription for peptides?

Yes, for any compounded peptide covered by the HHS policy. The policy keeps the patient-specific prescription requirement of section 503A.

Does the HHS policy cover BPC-157 + TB-500 blends?

No. Each compounded product may contain only one active ingredient from the list, so two-peptide blends are outside the policy.

Can the policy be withdrawn?

Yes. It is a draft, non-binding enforcement policy. HHS can revise it after the comment period or if safety or quality problems emerge, and it ends for each peptide once the FDA issues a final rule.

Related Research

Research use only

All products on this site are sold strictly for laboratory research and are not for human or veterinary use. This article summarizes public regulatory documents and news reports. It is not legal or medical advice.

Sources

  1. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, FR Doc. 2026-22192, October 30, 2026. federalregister.gov
  2. Venable LLP. HHS Announces Interim Enforcement Discretion for Section 503A Compounding with Certain Peptide Bulk Drug Substances. November 2026. venable.com
  3. Orrick. FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting. July 21, 2026; RAPS Regulatory Focus, July 24, 2026. raps.org
  4. Arnold & Porter. HHS Announces Draft Enforcement Discretion Policy. November 2, 2026. arnoldporter.com
  5. Associated Press. FDA scientists opposed the Trump administration's effort to ease peptides access. October 28, 2026. via clickondetroit.com; Boston Globe, October 28, 2026. bostonglobe.com
  6. Frier Levitt. HHS Announces Landmark Peptide Enforcement Discretion Policy. 2026. frierlevitt.com
  7. BakerHostetler. HHS Issues Enforcement Discretion Policy Regarding 503A Compounding. 2026. bakerlaw.com
  8. National Law Review. HHS Draws New Lines for Peptide Compounding: What Changes for 503A Pharmacies. November 9, 2026. natlawreview.com
  9. Holland & Knight. HHS Issues Interim Enforcement Discretion Policy for Compounding. November 4, 2026. hklaw.com
  10. McDermott Will & Schulte. FDA warning letters to online peptide sellers. 2026. mcdermottlaw.com
  11. Eli Lilly and Company. Retatrutide successful in two additional phase 3 obesity trials. July 23, 2026. investor.lilly.com
  12. USADA. BPC-157: What Athletes Should Know. usada.org; WADA Prohibited List. wada-ama.org
  13. The New Daily. Aussie actor's death linked to unapproved peptides. October 29, 2026. thenewdaily.com.au
  14. NL Times. Many new sites selling weight-loss drugs; authorities drowning in peptides from China. November 5, 2026. nltimes.nl
  15. Partnership for Safe Medicines. November 2, 2026 newsletter. safemedicines.org
  16. CSPI. Letter to FDA re: Meeting of the Pharmacy Compounding Advisory Committee on Peptides. 2026. cspi.org
  17. Narrative review of BPC-157, thymosin beta-4 and TB-500 in orthopaedics. J Am Acad Orthop Surg, online October 27, 2026. pubmed.ncbi.nlm.nih.gov/42937313
  18. Hims & Hers. Peptides+ (waitlist page). hims.com
  19. Becker's Hospital Review. Hims & Hers to sell compounded peptides pending FDA approval. August 2026. beckershospitalreview.com